Heart Failure Academy

This #HeartFailureAwarenessWeek the HFA welcomed colleagues from S Yorkshire to upskill in HF in our online Planned Learning Time and face to face events. We learnt from local specialists and the wonderful PM patient educators. Join us at future events hfacademy.co.uk/events/

Let's all upskill and ensure early recognition of heart failure signs and symptoms to ensure better outcomes for patients. Join us at the Heart Failure Academy events and learn more. Just a few places left at our next study day 8 May in West Yorkshire hfacademy.co.uk/events/

💥 Should we start SGLT2i DURING hospitalization for acute heart failure? 🔍 New systematic review & meta-analysis: 8 RCTs | n = 4,096 patients ✅ In-hospital SGLT2i initiation significantly reduces: • All-cause death → RR 0.61 (95% CI 0.47–0.81) • Worsening HF events → RR 0.67 (95% CI 0.45–0.94) • Cardiovascular death → RR 0.68 (95% CI 0.47–0.99) 🟡 No significant reduction in HF rehospitalization (RR 0.87) ⚠️ No increase in acute kidney injury or serious adverse events 💡 Key message: early in-hospital initiation of SGLT2i is safe and reduces mortality — don’t wait for discharge! 📄 Ahmed et al. Journal of Cardiac Failure, 2026 #Cardiology #HeartFailure #SGLT2i #AcuteHF #GDMT #CardioTwitter

⚠️ Are we missing heart failure events in clinical trials? @JavedButler1 @safchat @mvaduganathan @gcfmd @SJGreene_md 🔍 Traditional HF endpoints (hospitalization + IV diuretics) fail to capture patients managed in the outpatient setting 📊 Why this matters: • ~62% of incident HF diagnoses are made OUTSIDE acute care • 1-year mortality in outpatients without hospitalization: ~6.4% • First HF event is more often oral diuretic intensification (13% vs. 1% IV visit) • SGLT2i & ARNi reduce diuretic need → events become even harder to detect! ✅ Proposed solution: adopt a BROADER HF endpoint including: → Clinician-confirmed outpatient diagnoses → HF managed without hospitalization ⚖️ Pros: more sensitive, captures real-world burden ⚠️ Cons: lower specificity, risk of false positives → requires rigorous adjudication 📄 Butler J, et al. JACC. 2026;87(15):1907–1935. #Cardiology #HeartFailure #ClinicalTrials #Endpoints #SGLT2i #CardioTwitter

During this Heart Failure week please visit our Heart Failure Academy website with plenty of resources aimed at generalists. Here is a sample of the webinars we delivered 👇 hfacademy.co.uk/library-of-hea… #HFAW #25in25 #BEATHF

This Heart Failure Awareness week register to attend a Heart Failure Academy event so you can develop your confidence in supporting people living with heart failure hfacademy.co.uk/events/

This Heart Failure Awareness week commit to learning how we can improve recognition of the signs and symptoms of heart failure and ensure people with HF get the right treatment at the right time to live well. Register now for upcoming events at hfacademy.co.uk/events/

29 million people worldwide have HFrEF. Most aren’t on the meds proven to save their lives. •91% not on SGLT2i (21.2M people) •89% not on ARNi (20.4M people) •57% not on MRA (12.2M people) Optimal quadruple GDMT could save 1.2 million lives per year. Western Pacific, Southeast Asia, and E. Mediterranean/Africa carry the heaviest burden — where the implementation gap is largest. We have the drugs. We have the data. The barrier is implementation. #HeartFailure #HFrEF #GDMT #Cardiology #ImplementationScience

Heart failure awareness week 27th April to May 3rd ! If cancer were treated like heart failure there would be a national outcry ! Please help raise awareness we can make a difference and save lives ❤️

Awareness today protects health tomorrow. During @esccardio’s #HeartFailureAwarenessDays, take a look at our resources to learn more about HF and support our mission to achieve earlier diagnosis, prevention and better care for all. hfpolicynetwork.org/what-is-heart-…

🚨 New data on heart failure & quadruple therapy is striking: 82% of HF patients are eligible for quadruple GDMT — yet only 15.3% receive it at discharge. The cost of undertreating? A 24.8% absolute risk reduction in 12-month all-cause mortality with quadruple vs. no GDMT. We have the tools. We're not using them. Triple therapy (RASi + BB + MRA) reaches 41.5% — still leaving massive gaps. SGLT2i uptake must catch up. Every patient who doesn't get quadruple therapy is a preventable death. #HeartFailure #GDMT #Cardiology #HFrEF #SGLT2i #MedTwitter

This Heart Failure Awareness week join MDT colleagues at the Heart Failure Academy study days and develop your knowledge to identify and support people living with heart failure

@BSHeartFailure So powerful, thank you @BSHeartFailure

We are delighted to announce the release of our film Detect the Undetected: Find Me. This compelling film showcases real-life stories of three remarkable couples who share their journey of recognising heart failure symptoms, urging their loved one to seek medical attention, which, in many cases, was a crucial step in saving their lives. #FindMe #IWasFound @thebeautifultruthmag

We want to highlight some of the priorities for Heart Failure care during this Heart Failure Awareness Week. The first priority is to improve recognition of Heart Failure and its symptoms with things like: - National symptom awareness (such as our BEAT HF campaign) - Mandatory Heart Failure education across primary care - Using clear, simple language that patients actually understand #BEATHF #HeartFailureAwarenessWeek Read more here 👇 buff.ly/TNVJXJb

Heart Failure Academy study days - who's in? hfacademy.co.uk/events/

👀Heart Failure Academy Study Day - have you registered yet? hfacademy.co.uk/events/

Personalised care and empowered citizens are key to improving #HeartFailure outcomes. This #EuropeanPatientsRightsDay, we call for policy to ensure access to high-quality HF care for all. hfpolicynetwork.org

2026 AACE Diabetes Algorithm — the comorbidities-first approach is a game changer for T2D management. No longer just “lower the A1C.” We now select therapy based on complications & comorbidities first, independent of glycemic targets. ▸ Heart Failure → SGLT2i (+ GLP-1 RA / GIP/GLP-1 RA) ▸ CKD → SGLT2i (+ GLP-1 RA) ▸ ASCVD / High Risk → GLP-1 RA (+ SGLT2i) ▸ Stroke/TIA → GLP-1 RA or Pioglitazone ▸ MASLD → GLP-1 RA / GIP/GLP-1 RA or Pioglitazone Key pearl: A1C >9%? Start ≥2 agents. Severe hyperglycemia → consider basal insulin early. Don’t let titration lag cost your patient. Bottom line: treat the whole patient, not just the glucose. 💊 #Diabetes #T2D #Endocrinology #AACE2026 #MedEd #ClinicalPearls

Remember, our @bhf funded #FINDAF algorithm, that detects undiagnosed #AFib , was developed & internally validated in 2M people in the UK, externally validated in 13M people across 4 continents & then prospectively tested in 2000 people in Yorkshire… & yes it works, very well.

Delighted to see the publication of our paper "Development of educational resources for patients and clinicians on injectable therapies with cardiovascular benefits". A collaboration with the @escardio @ACNAPPresident. Link 👇 diabetesonthenet.com/diabetes-prima…